Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma

Summary

RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving lenalidomide together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving lenalidomide together with rituximab works in treating patients with follicular or small lymphocytic non-Hodgkin lymphoma that has relapsed or not responded to treatment.

Timeline

Start

2008-08-25

Primary completion

2023-06-28

Completion

2024-04-15

Outcome

Outcome not reported

Stopped (Enrollment): “Poor accrual”

Drugs

Indications